Viatris (VTRS) Stock
Global manufacturer of generic medicines and biosimilars. Here's the price, business snapshot, and what's worth knowing about Viatris in October 2026.
Viatris Inc (VTRS) is a global pharmaceuticals company formed to manufacture, market and distribute a broad range of medicines, including generics, established brands and biosimilars. With a market cap of about $12.11 billion, the group operates at scale across multiple regions and emphasises manufacturing reach, product diversification and cost efficiency. Investors should know Viatris competes in price-sensitive markets where patent expiries, regulatory approvals and pricing pressure can affect margins. Management has focused on integrating operations and improving cash flow, but the company faces execution, regulatory and competitive risks. As with any equities, returns can vary and capital is at risk; this summary is general educational information, not personal investment advice. Potential investors should review the company’s latest financials, regulatory filings and consider their own objectives and risk tolerance or consult a professional before making decisions.
Viatris (VTRS) Stock Forecast
Analyst price target, next 12 months
$16.77
-6.8% vs today's $18.00
Price range over the last 12 months
Close to its 12-month high
Analysts covering Viatris have a consensus 12-month target of $16.77, below the current price of $18.00.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Viatris stock, expecting its value to rise from the current price.
Financial Health
Viatris is showing strong revenue and cash flow, indicating solid financial performance and stability.
Dividend
Viatris' dividend yield of 2.67% indicates a fair return for investors seeking dividends. If you invested $1000, you would be paid $26.70 a year in dividends (based on the last 12 months).
Baskets Featuring VTRS
HIV Therapeutics (Once-Daily Pill) Reshapes Market
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Published: 28 August 2026
Explore BasketGlobal Medtech UAE Healthcare Investment Basket 2025
The United Arab Emirates is making significant investments to upgrade its medical infrastructure, aiming to become a global healthcare destination. This basket provides exposure to the international US and EU-listed companies in pharmaceuticals, medtech, and digital health that supply this ambitious national project.
Published: 12 November 2025
Explore BasketPharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published: 21 October 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: 4 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Global manufacturing reach
Viatris’s wide geographic footprint helps distribution and scale, though regional regulations and pricing can influence returns.
Generics and biosimilars
Exposure to generics and emerging biosimilars offers volume opportunities, but pricing competition and approval timelines are important to watch.
Operational focus
Management has emphasised integration and cash generation to improve resilience, yet execution and market dynamics can affect results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
